These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 15252821

  • 41. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA.
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [Abstract] [Full Text] [Related]

  • 42. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients.
    Solai LK, Pollock BG, Mulsant BH, Frye RF, Miller MD, Sweet RA, Kirshner M, Sorisio D, Begley A, Reynolds CF.
    J Clin Psychopharmacol; 2002 Oct; 22(5):481-6. PubMed ID: 12352271
    [Abstract] [Full Text] [Related]

  • 43. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients.
    Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P.
    Pharmacol Res; 1995 Jun; 31(6):347-53. PubMed ID: 8685072
    [Abstract] [Full Text] [Related]

  • 44. Interaction of modafinil and clomipramine as comedication in a narcoleptic patient.
    Grözinger M, Härtter S, Hiemke C, Griese EU, Röschke J.
    Clin Neuropharmacol; 1998 Jun; 21(2):127-9. PubMed ID: 9579300
    [Abstract] [Full Text] [Related]

  • 45. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.
    Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM.
    J Clin Pharmacol; 2001 Apr; 41(4):443-51. PubMed ID: 11304901
    [Abstract] [Full Text] [Related]

  • 46. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.
    Brown JT, Schneiderhan M, Eum S, Bishop JR.
    Pharmacogenomics; 2017 May; 18(7):601-605. PubMed ID: 28470111
    [Abstract] [Full Text] [Related]

  • 47. Fluoxetine in endogenous depression and melancholia versus clomipramine.
    Ginestet D.
    Int Clin Psychopharmacol; 1989 Jan; 4 Suppl 1():37-40. PubMed ID: 2644338
    [No Abstract] [Full Text] [Related]

  • 48. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
    Wehmeier PM, Kluge M, Maras A, Riemann D, Berger M, Kohnen R, Dittmann RW, Gattaz WF.
    Pharmacopsychiatry; 2005 Jan; 38(1):13-6. PubMed ID: 15706460
    [Abstract] [Full Text] [Related]

  • 49. Fluoxetine versus clomipramine in major depressive disorders.
    Ropert R.
    Int Clin Psychopharmacol; 1989 Jan; 4 Suppl 1():89-95. PubMed ID: 2644343
    [No Abstract] [Full Text] [Related]

  • 50. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression.
    Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA.
    Pharmacogenomics J; 2002 Jan; 2(3):191-6. PubMed ID: 12082591
    [Abstract] [Full Text] [Related]

  • 51. Tolerance to desvenlafaxine in rapid metabolizing depressed patients.
    Parker GB, Brotchie HL, Hyett M.
    Int Clin Psychopharmacol; 2011 Mar; 26(2):84-7. PubMed ID: 21119521
    [Abstract] [Full Text] [Related]

  • 52. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
    Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, Chabert J, Dayer P, Hochstrasser D, Rossier MF.
    Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
    [Abstract] [Full Text] [Related]

  • 53. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico.
    Sosa-Macías M, Elizondo G, Flores-Pérez C, Flores-Pérez J, Bradley-Alvarez F, Alanis-Bañuelos RE, Lares-Asseff I.
    J Clin Pharmacol; 2006 May; 46(5):527-36. PubMed ID: 16638736
    [Abstract] [Full Text] [Related]

  • 54. [Clomipramine and desmethylclomipramine: relationship between plasma levels and clinical effect (author's transl)].
    Vandel B, Vandel S, Jounet JM, Allers G, Volmat R.
    Encephale; 1981 May; 7(5):601-8. PubMed ID: 7327152
    [Abstract] [Full Text] [Related]

  • 55. Metabolic interaction between fluoxetine and clomipramine: a case report.
    Balant-Gorgia AE, Ries C, Balant LP.
    Pharmacopsychiatry; 1996 Jan; 29(1):38-41. PubMed ID: 8852534
    [Abstract] [Full Text] [Related]

  • 56. [Toxic tricyclic drug plasma level caused by fluoxetine].
    Hambrecht M.
    Psychiatr Prax; 1995 Nov; 22(6):252-3. PubMed ID: 8570758
    [Abstract] [Full Text] [Related]

  • 57. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
    Fux R, Mörike K, Pröhmer AM, Delabar U, Schwab M, Schaeffeler E, Lorenz G, Gleiter CH, Eichelbaum M, Kivistö KT.
    Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
    [Abstract] [Full Text] [Related]

  • 58. Clinical importance of genetic polymorphism of drug oxidation.
    Edeki T.
    Mt Sinai J Med; 1996 Oct; 63(5-6):291-300. PubMed ID: 8898530
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.